UCB Dirección

Dirección controles de criterios 4/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Jean-Christophe Tellier

Chief Executive Officer (CEO)

€6.7m

Compensación total

Porcentaje del salario del CEO	19.4%
Permanencia del CEO	9.3yrs
Participación del CEO	n/a
Permanencia media de la dirección	8.1yrs
Promedio de permanencia en la Junta Directiva	10yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Jean-Christophe Tellier en comparación con los beneficios de UCB?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	€7m	€1m	€343m
Jun 30 2023	n/a	n/a	€332m
Mar 31 2023	n/a	n/a	€376m
Dec 31 2022	€6m	€1m	€420m
Jun 30 2022	n/a	n/a	€887m
Mar 31 2022	n/a	n/a	€971m
Dec 31 2021	€6m	€1m	€1b
Sep 30 2021	n/a	n/a	€996m
Jun 30 2021	n/a	n/a	€936m
Mar 31 2021	n/a	n/a	€834m
Dec 31 2020	€7m	€1m	€732m
Jun 30 2020	n/a	n/a	€743m
Mar 31 2020	n/a	n/a	€767m
Dec 31 2019	€87k	n/a	€790m
Jun 30 2019	n/a	n/a	€652m
Mar 31 2019	n/a	n/a	€722m
Dec 31 2018	€76k	n/a	€792m
Jun 30 2018	n/a	n/a	€872m
Mar 31 2018	n/a	n/a	€812m
Dec 31 2017	€76k	n/a	€752m

Compensación vs. Mercado: La compensación total de Jean-Christophe ($USD7.22M) es aproximadamente el promedio para empresas de tamaño similar en el mercado UK ($USD5.68M).

Compensación vs. Ingresos: Jean-Christopheha sido coherente con los resultados de la empresa en el último año.

CEO

Jean-Christophe Tellier (64 yo)

9.3yrs

Permanencia

€6,662,655

Compensación

Mr. Jean-Christophe Tellier has been the Chief Executive Officer and Executive Director of UCB SA since January 1, 2015 and April 24, 2014 respectively and also was an Interim Chief Financial Officer since...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Jean-Christophe Tellier	CEO & Executive Director	9.3yrs	€6.66m	sin datos
Sandrine Dufour	Executive VP	3.8yrs	sin datos	sin datos
Kirsten Lund-Jurgensen	Executive Vice President of Supply & Technology Solutions	4.6yrs	sin datos	sin datos
Dhavalkumar Patel	Executive VP & Chief Scientific Officer	6.5yrs	sin datos	sin datos
Denelle J. Johnson	Executive VP & General Counsel	less than a year	sin datos	sin datos
Jean-Luc Fleurial	Executive VP & Chief Human Resources Officer	4.2yrs	sin datos	sin datos
Iris Low-Friedrich	Executive VP & Chief Medical Officer	16.1yrs	sin datos	sin datos
Emmanuel Caeymaex	Executive VP of Immunology Solutions & Head of US	9.2yrs	sin datos	sin datos
Caroline Vancoillie	Chief Accounting Officer	11.1yrs	sin datos	sin datos
Antje Witte	Head of Investor Relations	14.3yrs	sin datos	sin datos
Gwendoline Ornigg	Head of Global Communication	no data	sin datos	sin datos
Raf Remijsen	Head of Treasury & Risk Management	8.1yrs	sin datos	sin datos

8.1yrs

Permanencia media

60yo

Promedio de edad

Equipo directivo experimentado: UCBBEl equipo directivo de la empresa es veterano y experimentado (7.8 años de antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Jean-Christophe Tellier	CEO & Executive Director	10yrs	€6.66m	sin datos
Gerhard Mayr	Honorary Chairman	no data	€70.00k	sin datos
Mark Eyskens	Honorary Chairman	19.3yrs	€15.50k	sin datos
Daniel Janssen	Honorary Deputy Chairman	no data	€28.50k	sin datos
Albrecht De Graeve	Director	14yrs	€85.00k	sin datos
Georges Jacobs Hagen	Honorary Chairman	no data	€30.00k	sin datos
Diégo du de Bergendal	Honorary Chairman	3yrs	€87.50k	sin datos
Karel Boone	Honorary Chairman	no data	€49.00k	sin datos
Dame Davies	Independent Director	10yrs	€138.00k	sin datos
Jonathan Peacock	Independent Chair of the Board	3yrs	€341.83k	sin datos
Charles-Antoine Emmanuel Janssen	Director	12yrs	€108.50k	sin datos
Jonkheer van Rijckevorsel	Director	10yrs	€86.00k	sin datos

10.0yrs

Permanencia media

72yo

Promedio de edad

Junta con experiencia: UCBBLos consejos de administración de la empresa son veteranos y experimentados ( 10 años de permanencia media en el cargo).

UCB Dirección

Dirección controles de criterios 4/4

Información clave

Actualizaciones recientes de la dirección

UCB Announces Resignation of Head of Neurology Solutions Charl Van Zyl

UCB SA, Annual General Meeting, Apr 27, 2023

UCB SA, Annual General Meeting, Apr 28, 2022

UCB Announces Changes on Board of Directors

Recent updates

UCB Announces FDA Accepts Supplemental Biologics License Applications for Bimzelx

UCB Announces 48-Week Phase 3 Analyses of Pooled Phase 3 Data from the BE HEARD I and BE HEARD II Studies

UCB Presents New Data About the Real-World Experience of FINTEPLA® (Fenfluramine) and Rare Epilepsy Syndromes At 2023 American Epilepsy Society (AES) Annual Meeting

UCB SA Announces U.S. Availability of BIMZELX for the Treatment of Adults with Moderate-To-Severe Plaque Psoriasis

UCB to Present Post Hoc Analysis of the EXXELERATE Trial Evaluating the Efficacy of CIMZIA®? (Certolizumab Pegol) and Adalimumab in Patients with Rheumatoid Arthritis and High Rheumatoid Factor

UCB Presents Latest Data from Generalized Myasthenia Gravis Portfolio

UCB SA Announces Publication of NAYZILAM® (midazolam) Results in 'Epilepsy & Behavior' Examining the Impact of Dose on Return to Full Baseline Function (RTFBF) for People with Seizure Clusters

UCB Announces U.S. FDA Approves BIMZELX (Bimekizumab-Bkzx) for the Treatment of Adults with Moderate-To-Severe Plaque Psoriasis

UCB Announces U.S. FDA approval of ZILBRYSQ® (zilucoplan) for the Treatment of Adults with Generalized Myasthenia Gravis

UCB Reinforces Commitment to Advancing Care in Hidradenitis Suppurativa with Six Abstracts at SHSA 2023

UCB Announces Phase 3 Data Analysis Presented at EADV 2023 Showed Bimekizumab Achieved High Thresholds of Clinical Response in Hidradenitis Suppurativa

UCB SA to Report Fiscal Year 2023 Results on Feb 21, 2024

Ucb Announces That Rystiggo Is Commercially Available for the Treatment of Adult Patients in the U.S. with Generalized Myasthenia Gravis (Gmg) Who Are Anti-Acetylcholine Receptor (Achr) or Anti-Muscle-Specific Tyrosine Kinase (Musk) Antibody Positive

UCB Announces Resignation of Head of Neurology Solutions Charl Van Zyl

Upcoming dividend of €0.93 per share at 1.5% yield

Full year 2022 earnings released: EPS: €2.22 (vs €5.58 in FY 2021)

UCB Announces Annals of the Rheumatic Diseases Publishes Results from Two Bimekizumab Phase 3 Studies in Axial Spondyloarthritis

UCB SA to Report Fiscal Year 2022 Results on Feb 22, 2023

UCB Announces Rozanolixizumab BLA for the Treatment of Generalized Myasthenia Gravis Filed with U.S. FDA and Designated for Priority Review

UCB Announces Positive Phase 3 Studies for Bimekizumab in Hidradenitis Suppurativa

UCB SA to Present Data At the American Epilepsy Society 76Th Annual Meeting 2022 Supporting A Decades-Long Commitment to Transforming Epilepsy Care

UCB Announces the Publication of Long-Term Open-Label Extension (OLE) Study Results of FINTEPLA® (Fenfluramine) CIV in Epilepsia

UCB Announces U.S. FDA Acceptance of New Drug Application and EMA MAA Validation for Zilucoplan for the Treatment of Generalized Myasthenia Gravis in Adult Patients

UCB Announces the First Presentation of Long-Term, 52-Week Data from Three Phase 3 Studies Evaluating the Efficacy and Safety of Bimekizumab in Adults with Active Psoriatic Arthritis

UCB Announces New Three-Year Results from the BE BRIGHT Open-Label Extension Study

First half 2022 earnings released

UCB, Announces New 24-Week Data from Two Phase 3 Studies, Be Mobile 1 and Be Mobile 2

UCB SA Announces First Detailed Data from Two Phase 3 Bimekizumab Studies in Psoriatic Arthritis to Be Presented At EULAR 2022

UCB SA, Annual General Meeting, Apr 27, 2023

UCB Presents Efficacy and Safety Results for Zilucoplan and Rozanolixizumab in Generalized Myasthenia Gravis

UCB Announces Jama Neurology Publishes Phase 3 Study Results on the Efficacy and Safety of Fintepla® (Fenfluramine) Oral Solution in Lennox-Gastaut Syndrome

UCB SA Announces Oral Solution Civ Approves for Treatment of Seizures Associated with Lennox-Gastaut Syndrome

UCB SA, Annual General Meeting, Apr 28, 2022

UCB Announces Positive Data in Myasthenia Gravis with Zilucoplan Phase 3 Study Results

UCB Announces Positive Top-Line Results for bimekizumab in Second Phase 3 Psoriatic Arthritis Study

UCB SA Announces Positive Top-Line Interim Analysis Results Showing That the Phase 3 Be Mobile 1 Study Met the Primary and All Ranked Secondary Endpoints

UCB SA Announces Positive Top-Line Interim Analysis Results from the Phase 3 Be Mobile 2 Study

UCB Announces Positive Phase 3 Results for Rozanolixizumab in Generalized Myasthenia Gravis

First half 2021 earnings released: EPS €3.00 (vs €1.92 in 1H 2020)

UCB Announces New Data from Rheumatology Portfolio Demonstrates Real World Value for Patients with axSpA, PsA, and Women of Childbearing Age

Independent Vice Chairman Pierre Gurdjian has left the company

Chairman Diégo du de Bergendal has left the company

Insilico's Chemistry42 AI system integrated into UCB's drug discovery programs

Revenue beats expectations

Full year 2020 earnings released: EPS €3.87 (vs €4.22 in FY 2019)

New 90-day low: €82.23

UCB Announces Changes on Board of Directors

New 90-day low: €84.30

UCB SA to Report First Half, 2021 Results on Jul 29, 2021

doc.ai and UCB Teams Up to Develop Breakthrough Artificial Intelligence Models to Advance Care

UCB and Stanford Medicine Establish Multi-Year Collaboration

UCB Announces U.S. Food and Drug Administration Approval of VIMPAT

UCB SA (ENXTBR:UCB) agreed to acquire Handl Therapeutics from Gemma Frisius Fonds NV.

UCB Announces New Data on Its TNF Inhibitor

Bimekizumab Phase 3 Data Shows Superior Skin Clearance over Humira® in Moderate-To-Severe Psoriasis Patients

UCB Announces That the FDA and EMA Have Accepted the Biologics License Application (BLA) and Marketing Authorization Application (MAA), Respectively, for Bimekizumab for the Treatment of Adults with Moderate to Severe Plaque Psoriasis

UCB SA to Report Fiscal Year 2020 Results on Feb 25, 2021

UCB SA (ENXTBR:UCB) completed the acquisition of Ra Pharmaceuticals, Inc. (NasdaqGM:RARX) from Douglas A. Treco, New Enterprise Associates 13, L.P. managed by New Enterprise Associates and RA Capital Healthcare Fund, L.P managed by Ra Capital Management, LLC and others.

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad